XCR Diagnostics
XCR Diagnostics develops easy-to-use, portable molecular diagnostic systems, delivering accurate pathogen detection in minutes.
Founded
2015XCR Diagnostics develops easy-to-use, portable molecular diagnostic systems, delivering accurate pathogen detection in minutes.
XCR Diagnostics was founded with the mission to revolutionize near-patient molecular diagnostic testing by developing easy-to-use, portable systems that deliver accurate pathogen detection in minutes. Their core technology, Xtreme Chain Reaction (XCR®), is a patented nucleic acid amplification chemistry that surpasses traditional amplification systems in efficiency. The company offers a portable bench-top system designed for clinical settings, providing rapid and reliable detection of pathogens from clinical specimens.
Notable individuals affiliated with XCR Diagnostics include J. Chuck Morrison, who serves on the Board of Directors. The company has achieved significant milestones, including the development of their advanced XCR® chemistry and the creation of affordable, single-use sample delivery systems. Their innovative approach has made a substantial impact on the molecular diagnostics market by enabling faster and more accessible testing, thereby improving patient outcomes and streamlining clinical workflows.
Companies similar to XCR Diagnostics include Fast PCR Diagnostics, DxNA, Co-Diagnostics and Crystal Diagnostics.
XCR Diagnostics was founded in 2015.
XCR Diagnostics' headquarters is located in Salt Lake City, UT, US.
XCR Diagnostics' most recent funding round was for $2.5M (USD) in November 2016.
As of Nov 22, 2016, XCR Diagnostics has disclosed funding of $2.5M (USD). Undisclosed round amounts are excluded.
XCR Diagnostics has 30 employees as of Feb 5, 2024.
